Bromocriptine Use and the Risk of Valvular Heart Disease
Identifieur interne : 000F60 ( PascalFrancis/Checkpoint ); précédent : 000F59; suivant : 000F61Bromocriptine Use and the Risk of Valvular Heart Disease
Auteurs : Louis C. S. Tan [Singapour, États-Unis] ; Kenneth K. C. Ng [Singapour] ; Wing-Lok Au [Singapour, États-Unis] ; Raymond K. K. Lee [Singapour] ; Yiong-Huak Chan [Singapour] ; Nigel C. K. Tan [Singapour]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT2B activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0136792Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Bromocriptine Use and the Risk of Valvular Heart Disease</title><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>USA National Parkinson Foundation Centre of Excellence</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1><s3>SGP</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Cardiology, Tan Tock Seng Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>USA National Parkinson Foundation Centre of Excellence</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1><s3>SGP</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Cardiology, Tan Tock Seng Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1><s3>SGP</s3><sZ>5 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0136792</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0136792 INIST</idno><idno type="RBID">Pascal:09-0136792</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F64</idno><idno type="wicri:Area/PascalFrancis/Curation">001D55</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Bromocriptine Use and the Risk of Valvular Heart Disease</title><author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>USA National Parkinson Foundation Centre of Excellence</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1><s3>SGP</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Cardiology, Tan Tock Seng Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>USA National Parkinson Foundation Centre of Excellence</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1><s3>SGP</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Cardiology, Tan Tock Seng Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1><s3>SGP</s3><sZ>5 aut.</sZ></inist:fA14><country>Singapour</country><orgName type="university">Université nationale de Singapour</orgName></affiliation></author><author><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Singapour</country><wicri:noRegion>Department of Neurology, National Neuroscience Institute</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT2 Serotonine receptor</term><term>Bromocriptine</term><term>Cardiac valvular disease</term><term>Dopamine agonist</term><term>Ergotamine</term><term>Nervous system diseases</term><term>Pergolide</term><term>Risk factor</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cardiopathie valvulaire</term><term>Pathologie du système nerveux</term><term>Bromocriptine</term><term>Facteur risque</term><term>Récepteur sérotoninergique 5-HT2</term><term>Ergotamine</term><term>Pergolide</term><term>Stimulant dopaminergique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT<sub>2B</sub> activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>24</s2></fA05><fA06><s2>3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Bromocriptine Use and the Risk of Valvular Heart Disease</s1></fA08><fA11 i1="01" i2="1"><s1>TAN (Louis C. S.)</s1></fA11><fA11 i1="02" i2="1"><s1>NG (Kenneth K. C.)</s1></fA11><fA11 i1="03" i2="1"><s1>AU (Wing-Lok)</s1></fA11><fA11 i1="04" i2="1"><s1>LEE (Raymond K. K.)</s1></fA11><fA11 i1="05" i2="1"><s1>CHAN (Yiong-Huak)</s1></fA11><fA11 i1="06" i2="1"><s1>TAN (Nigel C. K.)</s1></fA11><fA14 i1="01"><s1>Parkinson's Disease and Movement Disorders Centre, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>USA National Parkinson Foundation Centre of Excellence</s1><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Neurology, National Neuroscience Institute</s1><s3>SGP</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Cardiology, Tan Tock Seng Hospital</s1><s3>SGP</s3><sZ>2 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1><s3>SGP</s3><sZ>5 aut.</sZ></fA14><fA20><s1>344-349</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000186999840040</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>30 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0136792</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>It has been reported that patients on pergolide and carbergoline have an increased risk of developing valvular heart disease. It is uncertain if bromocriptine, an ergot-derived dopamine agonist (DA) with partial 5-HT<sub>2B</sub> activity, is associated with a similar risk. We assessed the frequency of valvular heart disease in Parkinson's disease (PD) patients on bromocriptine compared to pergolide and a control group of PD patients who had not been treated on any DA. Seventy-two PD patients on bromocriptine, 21 patients on pergolide, and 47 control PD patients were recruited. Transthoracic echocardiographic studies were performed and reviewed by a blinded cardiologist. The risk for the bromocriptine group to develop any abnormal valvular regurgitation was 3.32 (adjusted OR, 95% CI: 1.11-9.92, P = 0.03) compared to controls, whereas the risk for the pergolide group was 3.66 (adjusted OR, 95% CI: 1.22-10.97, P = 0.02). When cumulative dose of bromocriptine was analyzed by quartiles, patients with a greater exposure to bromocriptine had significantly higher risk of developing both mild and moderate-severe regurgitations (P for trend, 0.005 and 0.019, respectively). This study demonstrated that bromocriptine use was associated with an increased risk of developing valvular heart disease, which occurred in a cumulative dose-dependent manner.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Cardiopathie valvulaire</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Cardiac valvular disease</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Cardiopatía valvular</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Bromocriptine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Bromocriptine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Bromocriptina</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Facteur risque</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Risk factor</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Récepteur sérotoninergique 5-HT2</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>5-HT2 Serotonine receptor</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Receptor serotoninérgico 5-HT2</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Ergotamine</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Ergotamine</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Ergotamina</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Pergolide</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Pergolide</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Pergolida</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Dopamine agonist</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fN21><s1>096</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Singapour</li><li>États-Unis</li></country><orgName><li>Université nationale de Singapour</li></orgName></list><tree><country name="Singapour"><noRegion><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name></noRegion><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name><name sortKey="Lee, Raymond K K" sort="Lee, Raymond K K" uniqKey="Lee R" first="Raymond K. K." last="Lee">Raymond K. K. Lee</name><name sortKey="Ng, Kenneth K C" sort="Ng, Kenneth K C" uniqKey="Ng K" first="Kenneth K. C." last="Ng">Kenneth K. C. Ng</name><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name><name sortKey="Tan, Nigel C K" sort="Tan, Nigel C K" uniqKey="Tan N" first="Nigel C. K." last="Tan">Nigel C. K. Tan</name></country><country name="États-Unis"><noRegion><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name></noRegion><name sortKey="Au, Wing Lok" sort="Au, Wing Lok" uniqKey="Au W" first="Wing-Lok" last="Au">Wing-Lok Au</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000F60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0136792
|texte= Bromocriptine Use and the Risk of Valvular Heart Disease
}}
| This area was generated with Dilib version V0.6.23. |  |